Compare IPCA Labs with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CIPLA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CIPLA IPCA LABS/
CIPLA
 
P/E (TTM) x 23.1 34.7 66.6% View Chart
P/BV x 8.3 4.9 168.5% View Chart
Dividend Yield % 0.1 0.4 35.2%  

Financials

 IPCA LABS   CIPLA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
CIPLA
Mar-20
IPCA LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,042586 178.0%   
Low Rs590357 165.4%   
Sales per share (Unadj.) Rs298.6207.0 144.2%  
Earnings per share (Unadj.) Rs35.018.6 188.2%  
Cash flow per share (Unadj.) Rs49.433.2 149.1%  
Dividends per share (Unadj.) Rs3.004.00 75.0%  
Dividend yield (eoy) %0.40.8 43.3%  
Book value per share (Unadj.) Rs247.1195.5 126.4%  
Shares outstanding (eoy) m126.35806.35 15.7%   
Bonus / Rights / Conversions ESOSESOS-  
Price / Sales ratio x2.72.3 120.1%   
Avg P/E ratio x23.325.3 92.0%  
P/CF ratio (eoy) x16.514.2 116.2%  
Price / Book Value ratio x3.32.4 137.0%  
Dividend payout %8.621.5 39.8%   
Avg Mkt Cap Rs m103,108379,912 27.1%   
No. of employees `00013.425.8 52.0%   
Total wages/salary Rs m7,87430,270 26.0%   
Avg. sales/employee Rs Th2,807.06,459.6 43.5%   
Avg. wages/employee Rs Th585.81,171.2 50.0%   
Avg. net profit/employee Rs Th329.0580.2 56.7%   
INCOME DATA
Net Sales Rs m37,732166,949 22.6%  
Other income Rs m5773,442 16.8%   
Total revenues Rs m38,309170,391 22.5%   
Gross profit Rs m6,90132,060 21.5%  
Depreciation Rs m1,82411,747 15.5%   
Interest Rs m1891,974 9.6%   
Profit before tax Rs m5,46521,782 25.1%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0426,312 16.5%   
Profit after tax Rs m4,42214,995 29.5%  
Gross profit margin %18.319.2 95.2%  
Effective tax rate %19.129.0 65.8%   
Net profit margin %11.79.0 130.5%  
BALANCE SHEET DATA
Current assets Rs m23,778117,038 20.3%   
Current liabilities Rs m10,97543,931 25.0%   
Net working cap to sales %33.943.8 77.5%  
Current ratio x2.22.7 81.3%  
Inventory Days Days10496 108.4%  
Debtors Days Days6685 77.5%  
Net fixed assets Rs m20,368107,424 19.0%   
Share capital Rs m2531,613 15.7%   
"Free" reserves Rs m30,971156,018 19.9%   
Net worth Rs m31,224157,630 19.8%   
Long term debt Rs m1,40923,693 5.9%   
Total assets Rs m45,507236,626 19.2%  
Interest coverage x30.012.0 248.9%   
Debt to equity ratio x00.2 30.0%  
Sales to assets ratio x0.80.7 117.5%   
Return on assets %10.17.2 141.3%  
Return on equity %14.29.5 148.9%  
Return on capital %17.312.8 134.9%  
Exports to sales %45.933.0 138.8%   
Imports to sales %16.60-   
Exports (fob) Rs m17,30855,175 31.4%   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30856,036 30.9%   
Fx outflow Rs m6,2666,764 92.6%   
Net fx Rs m11,04249,272 22.4%   
CASH FLOW
From Operations Rs m4,92330,685 16.0%  
From Investments Rs m-1,5631,040 -150.2%  
From Financial Activity Rs m-1,832-29,488 6.2%  
Net Cashflow Rs m1,5282,340 65.3%  

Share Holding

Indian Promoters % 45.9 16.0 286.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.4 12.2 93.4%  
FIIs % 25.3 23.7 106.8%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.4 26.2 66.4%  
Shareholders   36,892 161,166 22.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Adani Ports and Tata Steel Among Top Nifty Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors(Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments(Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels(Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth(Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 16, 2021 03:36 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ELDER PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS